The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies.
Blackney M, Kelly M, Zeidman R, Andreykiv M, Plich A
Value Health. 2014 Nov; 17(7):A393. PMID: 27200915.Abstract
